Nexbio, Inc.
Records under this name other than patents Nexbio, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,623,419 | Technology for preparation of macromolecular microspheres Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,583,086 | Technology for preparation of macromolecular microspheres Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,398,971 | Methods, compounds, and compositions for treatment and prophylaxis in the respiratory tract Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,700,602 | Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,351,828 | Method of protein purification from E. coli Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,807,174 | Novel Class of Therapeutic Protein Based Molecules Formerly held Term ended Term ended Feb 9, 2026 · High confidence | Term ended | Term ended Feb 9, 2026 | High confidence |
| US 7,645,448 | Novel Class of Therapeutic Protein Based Molecules Formerly held Term ended Term ended Sep 10, 2024 · High confidence | Term ended | Term ended Sep 10, 2024 | High confidence |
| US 8,512,710 | Novel Class of Therapeutic Protein Based Molecules Formerly held Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |
| US 8,722,869 | Novel Class of Therapeutic Protein Based Molecules Formerly held Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |
| US 9,212,353 | Novel Class of Therapeutic Protein Based Molecules Formerly held Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |